Clinical Trials Logo

Clinical Trial Summary

The primary objective of the study is to evaluate the efficacy of BIIB104 in participants with CIAS, using the Working Memory Domain of the MATRICS Consensus Cognitive Battery (MCCB). The secondary objectives of this study are to evaluate the safety and tolerability of BIIB104 in participants with CIAS, and to evaluate the efficacy of BIIB104 in participants with CIAS on measures of cognition, functioning, and psychiatric symptomology.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT03745820
Study type Interventional
Source Biogen
Contact
Status Completed
Phase Phase 2
Start date November 15, 2018
Completion date April 7, 2022

See also
  Status Clinical Trial Phase
Active, not recruiting NCT00604760 - Study to Evaluate the Safety and Efficacy of MEM 3454 as Adjunctive Treatment in Combination With a Preexisting Antipsychotic in Patients With Cognitive Impairment Associated With Schizophrenia Phase 2
Completed NCT05136690 - Evoked Responses as Pharmacodynamic Biomarkers in Healthy and Schizophrenic Participants (MK-4334-007) Phase 1